Intranasal oxytocin
( DrugBank: - / KEGG DRUG: - )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
127 | 前頭側頭葉変性症 | 5 |
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
193 | プラダー・ウィリ症候群 | 18 |
127. 前頭側頭葉変性症
臨床試験数 : 123 / 薬物数 : 107 - (DrugBank : 33) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 89
Showing 1 to 5 of 5 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-000143-12-IT (EUCTR) | 25/07/201920190725 | 12/06/202320230612 | Efficacy of intranala oxytocin in dementia. A randomized double-blind, placebo-controlled trial. | OXYTOCIN RESEARCH FOR BEHAVIORAL IMPAIRMENT SYMPTOMS IN DEMENTIA: Potential clinical efficacy of intranasal oxytocin in the treatment of frontotemporal dementia. A randomized, double-blind, placebo-controlled crossover trial. - ORBIS-DE-UNIBO001 OXYTOCINRESEARCH FOR BEHAVIORAL IMPAIRMENT SYMPTOMS IN DEMENTIA: Potential clinical efficacy of intr ... | Frontotemporal dementia (bvFTD) MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Frontotemporal dementia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Frontotemporal dementia (bvFTD) MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Fr ... | INN or Proposed INN: OSSITOCINA Other descriptive name: Syntocinon | ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA | NULL | Not Recruiting | Female: yes Male: yes | 52 | Phase 2 | Italy | ||
2 | NCT03260920 (ClinicalTrials.gov) | January 31, 201820180131 | 19/7/201720170719 | Intranasal Oxytocin for Frontotemporal Dementia | A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia | Frontotemporal Dementia | Drug: Syntocinon | Lawson Health Research Institute | Weston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry Consultants | Active, not recruiting | 30 Years | 80 Years | All | 112 | Phase 2 | United States;Canada |
3 | NCT01937013 (ClinicalTrials.gov) | September 12, 201320130912 | 3/9/201320130903 | Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia | Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia | Frontotemporal Dementia | Drug: Intranasal oxytocin;Drug: Saline Nasal Mist | Lawson Health Research Institute | Canadian Institutes of Health Research (CIHR) | Completed | 30 Years | 85 Years | All | 52 | Phase 2 | Canada |
4 | NCT01386333 (ClinicalTrials.gov) | June 201120110600 | 29/6/201120110629 | Safety Study of Intranasal Oxytocin in Frontotemporal Dementia | A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF A Phase I Dose Finding Study of Intranasal Oxytocinin Frontotemporal Dementia, Protocol # FTDOXY10EF ... | Frontotemporal Dementia | Drug: oxytocin;Drug: Saline Nasal Mist | Lawson Health Research Institute | The Consortium of Canadian Centres for Clinical Cognitive Research (C5R) | Completed | 30 Years | 80 Years | Both | 23 | Phase 1 | Canada |
5 | NCT01002300 (ClinicalTrials.gov) | September 200920090900 | 23/10/200920091023 | Oxytocin and Social Cognition in Frontotemporal Dementia | Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia Investigation of the Effects of Intranasal Oxytocinon Cognition and Emotion Processing in Frontotemp ... | Frontotemporal Dementia;Pick's Disease | Drug: intranasal oxytocin | Lawson Health Research Institute | The Alzheimer Society London and Middlesex | Completed | 30 Years | 80 Years | Both | 24 | N/A | Canada |
193. プラダー・ウィリ症候群
臨床試験数 : 128 / 薬物数 : 94 - (DrugBank : 25) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 102
Showing 1 to 10 of 18 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05298085 (ClinicalTrials.gov) | April 5, 202220220405 | 17/3/202220220317 | Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome | Effect of Intranasal Oxytocin on Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Children and Adolescents With Prader-Willi Syndrome: a Phase 2B Study Effect of Intranasal Oxytocinon Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Children ... | Prader-Willi Syndrome | Drug: Oxytocin nasal spray;Drug: Placebo | University Hospital, Toulouse | NULL | Completed | 2 Years | 17 Years | All | 25 | Phase 2/Phase 3 | France |
2 | EUCTR2021-000094-91-FR (EUCTR) | 25/01/202220220125 | 01/04/202120210401 | EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA IN CHILDREN AND ADOLESCENTS WITH PRADER WILLI SYNDROME | EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN CHILDREN AND ADOLESCENTS WITH PRADER-WILLI SYNDROME: A PHASE 3 STUDY (DYSMOT) - DYSMOT EFFECT OF INTRANASAL OXYTOCINON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN ... | Prader-Willi Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: OXYTOCIN Product Code: H01BB02 | Toulouse University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 36 | Phase 3 | France | ||
3 | EUCTR2019-002385-12-NL (EUCTR) | 26/08/202120210826 | 08/09/202020200908 | Oxytocin treatment in neonates and infants aged from 0 to 3 months with prader-willi syndrome | Oxytocin treatment in neonates and infants aged from 0 to 3 months with prader-willi syndrome: a study of the safety and efficacy on oral and social skills and, feeding behavior of intranasal administrations of oxytocin vs. placebo (phase iii clinical trial) - OTBB3 Oxytocintreatment in neonates and infants aged from 0 to 3 months with prader-willi syndrome: a stud ... | Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Oxytocin INN or Proposed INN: OXYTOCIN Other descriptive name: OXYTOCIN | University Hospital of Toulouse | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 3 | France;Belgium;Germany;Netherlands | ||
4 | EUCTR2019-002385-12-DE (EUCTR) | 07/07/202120210707 | 21/04/202120210421 | OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME | OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL) - OTBB3 OXYTOCINTREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUD ... | Prader-Willi Syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Oxytocin INN or Proposed INN: OXYTOCIN Other descriptive name: OXYTOCIN | University Hospital of Toulouse | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 3 | France;Belgium;Netherlands;Germany;Italy | ||
5 | EUCTR2019-002385-12-FR (EUCTR) | 27/08/201920190827 | 12/06/201920190612 | OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME | OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL) - OTBB3 OXYTOCINTREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUD ... | Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Oxytocin INN or Proposed INN: OXYTOCIN Other descriptive name: OXYTOCIN | University Hospital of Toulouse | NULL | Not Recruiting | Female: yes Male: yes | 48 | Phase 3 | France;Belgium;Germany;Netherlands;Italy | ||
6 | NCT03197662 (ClinicalTrials.gov) | April 11, 201820180411 | 19/6/201720170619 | Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome | Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Phase 2 Study: Intranasal Oxytocinvs. Placebo for the Treatment of Hyperphagia in Children and Adole ... | Prader-Willi Syndrome;Hyperphagia | Drug: Intranasal Oxytocin (IN-OXT);Drug: Matched Placebo | Eric Hollander | NULL | Completed | 5 Years | 17 Years | All | 32 | Phase 2 | United States |
7 | EUCTR2017-003423-30-NL (EUCTR) | 12/12/201720171212 | 04/10/201720171004 | Intranasal administration of oxytocin in children with Prader-Willi syndrome | Randomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome.Effects on social behaviour. Randomized, double-blind, placebo-controlled oxytocinand dose-response trial in children with Prader ... | Prader-Willi syndrome MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Prader-Willi syndrome MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi ... | Trade Name: Syntocinon nasal spray Product Name: oxytocin Product Code: oxytocin | Dutch Growth Research Foundation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 33 | Phase 2;Phase 3 | Netherlands | ||
8 | NCT03245762 (ClinicalTrials.gov) | August 1, 201720170801 | 7/8/201720170807 | Intranasal Oxytocin for Infants With Prader-Willi Syndrome | Intranasal Oxytocin for Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional Phase 1a - Phase 2 Study Intranasal Oxytocinfor Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional P ... | Prader-Willi Syndrome | Drug: Oxytocin;Drug: Placebo | University of Florida | Prader-Willi Syndrome Association | Completed | N/A | 6 Months | All | 15 | Phase 1/Phase 2 | United States |
9 | EUCTR2016-003820-22-NL (EUCTR) | 22/12/201620161222 | 12/10/201620161012 | Intranasal administration of oxytocin in children with Prader-Willi Syndrome | Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eating behaviour and social behaviour. - Intranasal administration of oxytocin in children with PWS Intranasaladministration of oxytocinin children with Prader-Willi Syndrome. A randomized, open-label ... | Prader-Willi syndrome MedDRA version: 19.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] Prader-Willi syndrome MedDRA version: 19.0;Level: PT;Classification code 10036476;Term: Prader-Willi ... | Trade Name: Syntocinon nasal spray Product Name: oxytocin Product Code: oxytocin | Dutch Growth Research Foundation | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Netherlands | |||
10 | NCT03114371 (ClinicalTrials.gov) | November 28, 201620161128 | 10/3/201720170310 | Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years | Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years. Effects of IntranasalAdministrations of Oxytocinon Behavioural Troubles, Hyperphagia and Social Skil ... | Prader-Willi Syndrome | Drug: Oxytocin;Drug: Placebo | University Hospital, Toulouse | NULL | Completed | 3 Years | 12 Years | All | 40 | N/A | France |